Alzheimer’s Disease is the most common cause of dementia. In its 2022 report, Alzheimer’s Disease international (ADI) estimated that there were over 55 million people living with dementia globally, a figure set to increase to 139 million by 2050. The World Health Organization (WHO) estimated the global societal cost of dementia in 2019 to be US$1.3 trillion (1).
ADI estimated that 75% of people with dementia were not diagnosed globally.
Recent progress in the biomarker field, especially blood-based biomarker may help to better diagnose the disease in the future.
There is currently no cure for Alzheimer’s Disease, and five symptomatic treatments are approved by the U.S. Food and Drug Administration (FDA).
The Amyloid-beta antibody Aduhelm has been approved by the FDA in June 2021, however it is not widely used and reimbursed. Other Amyloid-beta antibodies are in late clinical development and may be approved in 2023 (2).
Multiple other target drugs aiming at slowing down the progression of the disease are in clinical development (2).
At discoveric bio alpha we develop novel antibody-based therapeutics to slow down the progression of this complex disease.
Source:
